title: Pharmaceutical Approval Update.
abstract: Calcifediol (Rayaldee) for secondary hyperparathyroidism in adults with chronic kidney disease; dasabuvir/ombitasvir/paritaprevir/ritonavir (Viekira XR) for hepatitis C virus infection; and lixisenatide (Adlyxin) for type-2 diabetes.
authors.forename: Mary
authors.initials: M
authors.lastname: Choy